Systems Pharmacological Analysis of Drugs Inducing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Chemical Research in Toxicology

Volumn 28, Issue 5, 2015, Pages 927-934

  Hur, Junguk ^a,b   Zhao, Chunsheng ^c   Bai, Jane P F ^c  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMFEBUTAMONE; AMOXICILLIN; BRINZOLAMIDE; CAPTOPRIL; CARBAMAZEPINE; CATENIN CADHERIN ASSOCIATED PROTEIN BETA 1; CEFADROXIL; CLOZAPINE; DICLOFENAC; DRUG; ETOPOSIDE; GEFITINIB; HYDROCHLOROTHIAZIDE; IFOSFAMIDE; IOPROMIDE; LINCOMYCIN; MEDIATOR COMPLEX; MEFENAMIC ACID; MINOCYCLINE; NORFLOXACIN; PIPERACILLIN; PIROXICAM; REPAGLINIDE; RIFAMPICIN; ROFECOXIB; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ZIDOVUDINE; ANTICONVULSIVE AGENT; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; HLA DQ ANTIGEN; HLA-DQB1 ANTIGEN; MOLECULAR LIBRARY;

ARTICLE; CAUCASIAN; CELL ADHESION; CELL GROWTH; DATA MINING; DRUG ANALYSIS; DRUG DATABASE; DRUG IDENTIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE ONTOLOGY; GENETIC ASSOCIATION; HISTOCOMPATIBILITY GENE; HLA DQB1 GENE; HUMAN; HUMAN LEUKOCYTE ANTIGEN GENE; KNOWLEDGE BASE; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN FUNCTION; REGULATORY MECHANISM; SKIN EPITHELIUM; STEVENS JOHNSON SYNDROME; SYSTEM ANALYSIS; TOXIC EPIDERMAL NECROLYSIS; TRANSCRIPTOMICS; ADVERSE EFFECTS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR LIBRARY; RISK FACTOR; STEVENS-JOHNSON SYNDROME;

ANTICONVULSANTS; BETA CATENIN; CARBAMAZEPINE; DATABASES, PHARMACEUTICAL; GENE EXPRESSION REGULATION; HLA-DQ BETA-CHAINS; HUMANS; RISK FACTORS; SMALL MOLECULE LIBRARIES; STEVENS-JOHNSON SYNDROME;

EID: 84929575414     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx5005248     Document Type: Article

References (30)

1. Mockenhaupt, M. (2014) Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management Semin. Cutaneous Med. Surg. 33, 10 - 16
2. Goncalo, M., Coutinho, I., Teixeira, V., Gameiro, A. R., Brites, M. M., Nunes, R., and Martinho, A. (2013) HLA-B∗58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population Br. J. Dermatol. 169, 660 - 665
3. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y., and Chen, Y. T. (2004) Medical genetics: a marker for Stevens-Johnson syndrome Nature 428, 486
4. Genin, E., Chen, D. P., Hung, S. I., Sekula, P., Schumacher, M., Chang, P. Y., Tsai, S. H., Wu, T. L., Bellon, T., Tamouza, R., Fortier, C., Toubert, A., Charron, D., Hovnanian, A., Wolkenstein, P., Chung, W. H., Mockenhaupt, M., and Roujeau, J. C. (2014) HLA-A∗31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis Pharmacogenomics J. 14, 281 - 288
5. Pirmohamed, M., Friedmann, P. S., Molokhia, M., Loke, Y. K., Smith, C., Phillips, E., La Grenade, L., Carleton, B., Papaluca-Amati, M., Demoly, P., and Shear, N. H. (2011) Phenotype standardization for immune-mediated drug-induced skin injury Clin. Pharmacol. Ther. 89, 896 - 901
6. Hur, J., Guo, A. Y., Loh, W. Y., Feldman, E. L., and Bai, J. P. F. (2014) Integrated systems pharmacology analysis of clinical drug-induced peripheral neuropathy CPT: Pharmacometrics Syst. Pharmacol. 3, e114
7. Hur, J., Liu, Z., Tong, W., Laaksonen, R., and Bai, J. P. (2014) Drug-induced rhabdomyolysis: from systems pharmacology analysis to biochemical flux Chem. Res. Toxicol. 27, 421 - 32
8. Drugs@ FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (accessed July, 2014).
9. Kohl, M., Wiese, S., and Warscheid, B. (2011) Cytoscape: software for visualization and analysis of biological networks Methods Mol. Biol. 696, 291 - 303
10. Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., Djoumbou, Y., Eisner, R., Guo, A. C., and Wishart, D. S. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs Nucleic Acids Res. 39, D1035 - 1041
11. Qin, C., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y. H., Yang, S. Y., Wei, Y. Q., Tao, L., and Chen, Y. Z. (2014) Therapeutic target database update 2014: a resource for targeted therapeutics Nucleic Acids Res. 42, D1118 - 1123
12. Chatr-Aryamontri, A., Breitkreutz, B. J., Heinicke, S., Boucher, L., Winter, A., Stark, C., Nixon, J., Ramage, L., Kolas, N., O'Donnell, L., Reguly, T., Breitkreutz, A., Sellam, A., Chen, D., Chang, C., Rust, J., Livstone, M., Oughtred, R., Dolinski, K., and Tyers, M. (2013) The BioGRID interaction database: 2013 update Nucleic Acids Res. 41, D816 - 823
13. Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J. P., Subramanian, A., Ross, K. N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S. A., Haggarty, S. J., Clemons, P. A., Wei, R., Carr, S. A., Lander, E. S., and Golub, T. R. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Science 313, 1929 - 1935
14. Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., and di Bernardo, D. (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses Proc. Natl. Acad. Sci. U.S.A. 107, 14621 - 14626
15. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat. Protoc. 4, 44 - 57
16. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists Nucleic Acids Res. 37, 1 - 13
17. Su, G., Kuchinsky, A., Morris, J. H., States, D. J., and Meng, F. (2010) GLay: community structure analysis of biological networks Bioinformatics 26, 3135 - 3137
18. Pavlos, R., Mallal, S., and Phillips, E. (2012) HLA and pharmacogenetics of drug hypersensitivity Pharmacogenomics 13, 1285 - 1306
19. Chen, P., Lin, J. J., Lu, C. S., Ong, C. T., Hsieh, P. F., Yang, C. C., Tai, C. T., Wu, S. L., Lu, C. H., Hsu, Y. C., Yu, H. Y., Ro, L. S., Lu, C. T., Chu, C. C., Tsai, J. J., Su, Y. H., Lan, S. H., Sung, S. F., Lin, S. Y., Chuang, H. P., Huang, L. C., Chen, Y. J., Tsai, P. J., Liao, H. T., Lin, Y. H., Chen, C. H., Chung, W. H., Hung, S. I., Wu, J. Y., Chang, C. F., Chen, L., Chen, Y. T., and Shen, C. Y. (2011) Carbamazepine-induced toxic effects and HLA-B∗1502 screening in Taiwan N. Engl. J. Med. 364, 1126 - 1133
20. Aggarwal, R., Sharma, M., Modi, M., Garg, V. K., and Salaria, M. (2014) HLA-B∗1502 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population Hum. Immunol. 75, 120 - 2
21. Pichler, W. J., Beeler, A., Keller, M., Lerch, M., Posadas, S., Schmid, D., Spanou, Z., Zawodniak, A., and Gerber, B. (2006) Pharmacological interaction of drugs with immune receptors: the p-i concept Allergol. Int. 55, 17 - 25
22. Pichler, W. J., Naisbitt, D. J., and Park, B. K. (2011) Immune pathomechanism of drug hypersensitivity reactions J. Allergy Clin. Immunol. 127, S74 - 81
23. Shi, Y. W., Min, F. L., Qin, B., Zou, X., Liu, X. R., Gao, M. M., Wang, Q., Zhou, J. Q., and Liao, W. P. (2012) Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B∗1502? Basic Clin. Pharmacol. Toxicol. 111, 58 - 64
24. Paquet, P., Jacob, E., Quatresooz, P., Jacquemin, D., and Pierard, G. E. (2007) Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis Burns 33, 100 - 104
25. Liu, J., Wang, Y., Pan, Q., Su, Y., Zhang, Z., Han, J., Zhu, X., Tang, C., and Hu, D. (2012) Wnt/beta-catenin pathway forms a negative feedback loop during TGF-beta1 induced human normal skin fibroblast-to-myofibroblast transition J. Dermatol. Sci. 65, 38 - 49
26. Ko, T. M., Chung, W. H., Wei, C. Y., Shih, H. Y., Chen, J. K., Lin, C. H., Chen, Y. T., and Hung, S. I. (2011) Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome J. Allergy Clin. Immunol. 128, 1266 - 1276 e1211
27. McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperaviciute, D., Carrington, M., Sills, G. J., Marson, T., Jia, X., de Bakker, P. I., Chinthapalli, K., Molokhia, M., Johnson, M. R., O'Connor, G. D., Chaila, E., Alhusaini, S., Shianna, K. V., Radtke, R. A., Heinzen, E. L., Walley, N., Pandolfo, M., Pichler, W., Park, B. K., Depondt, C., Sisodiya, S. M., Goldstein, D. B., Deloukas, P., Delanty, N., Cavalleri, G. L., and Pirmohamed, M. (2011) HLA-A∗3101 and carbamazepine-induced hypersensitivity reactions in Europeans N. Engl. J. Med. 364, 1134 - 1143
28. Niihara, H., Kakamu, T., Fujita, Y., Kaneko, S., and Morita, E. (2012) HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population J. Dermatol. 39, 594 - 601
29. Yang, C. W., Hung, S. I., Juo, C. G., Lin, Y. P., Fang, W. H., Lu, I. H., Chen, S. T., and Chen, Y. T. (2007) HLA-B∗1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome J. Allergy Clin. Immunol. 120, 870 - 877
30. Wei, C. Y., Chung, W. H., Huang, H. W., Chen, Y. T., and Hung, S. I. (2012) Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome J. Allergy Clin. Immunol. 129, 1562 - 1569 e1565